Fig 1.
Flow chart of ICP cases included in the study.
Flow chart showing the intrahepatic cholestasis of pregnancy (ICP) cases at the Mother’s and Children’s Hospital, Buenos Aires, from June 2009 to December 2013, and reasons for the exclusion of some patients from the study.
Table 1.
Demographic and clinical characteristics of patients.
Fig 2.
Flow chart of management of patients.
Flow chart showing distribution of women with intrahepatic cholestasis of pregnancy (ICP) depending on whether they were not treated or treated with ursodeoxycholic acid (UDCA), together with days of treatment.
Table 2.
Comparison of obstetric outcomes.
Fig 3.
Relationship between hypercholanemia and body weight at birth.
Gestational age and body weight of neonates born from women with intrahepatic cholestasis of pregnancy (ICP) with high or low weights at birth for their gestational age.
Fig 4.
Relationship between hypercholanemia and the frequency of meconium-stained amniotic fluid (MSAF).
Frequency of the presence of MSAF in pregnancies complicated by cholestasis of pregnancy classified according to gestational age (GA) at diagnosis (A) or at delivery (B), severity of hypercholanemia (mild: 10–19.9 μmol/L; moderate: 20–39.9 μmol/L; severe: ≥40 μmol/L) at diagnosis in women not treated (C) or women treated with ursodeoxycholic acid (UDCA), (D), and at delivery in those treated with UDCA (E).
Fig 5.
Evaluation of the index to predict the risk of meconium-stained amniotic fluid (MSAF).
Balance between sensitivity and specificity for different cut-off values of meconium risk factor (MRF), calculated taking into account the severity of hypercholanemia and gestational age at diagnosis (A). Proportion of cases of MSAF in pregnancies with complications due to cholestasis of pregnancy according to a MRF cut-off value of 3 in women not treated or treated with ursodeoxycholic acid (UDCA) (B).